{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T03:37:25Z","timestamp":1779075445564,"version":"3.51.4"},"reference-count":141,"publisher":"IntechOpen","isbn-type":[{"value":"9781789852172","type":"print"},{"value":"9781789852189","type":"electronic"}],"license":[{"start":{"date-parts":[[2019,2,20]],"date-time":"2019-02-20T00:00:00Z","timestamp":1550620800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/3.0\/legalcode"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"DOI":"10.5772\/intechopen.75396","type":"book-chapter","created":{"date-parts":[[2019,2,7]],"date-time":"2019-02-07T09:45:05Z","timestamp":1549532705000},"source":"Crossref","is-referenced-by-count":2,"title":["Epidemiology of Multiple Myeloma"],"prefix":"10.5772","author":[{"given":"Rafael","family":"R\u00edos-Tamayo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dolores","family":"S\u00e1nchez Rodr\u00edguez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoe-Ling","family":"Chang- Chan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda-Jos\u00e9","family":"S\u00e1nchez P\u00e9rez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"3774","published-online":{"date-parts":[[2019,2,20]]},"reference":[{"key":"ref=1","doi-asserted-by":"crossref","unstructured":"Rajkumar SV, Dimopoulos MA, Palumbo A, Blad\u00e9 J, Merlini G, Mateos MV, et\u00a0al. International myeloma working group updated criteria for the diagnosis of multiple myeloma. The Lancet Oncology. 2014;15:e538-e548. DOI: 10.1016\/S1470-2045(14)70442-5","DOI":"10.1016\/S1470-2045(14)70442-5"},{"key":"ref=2","doi-asserted-by":"crossref","unstructured":"Bianchi G, Munshi NC.\u00a0Pathogenesis beyond the cancer clone(s) in multiple myeloma. Blood. 2015;125:3049-3058. DOI: 10.1182\/blood-2014-11-568881","DOI":"10.1182\/blood-2014-11-568881"},{"key":"ref=3","doi-asserted-by":"crossref","unstructured":"Kumar SK, Rajkumar V, Kyle RA, van Duin M, Sonneveld P, Mateos MV, et\u00a0al. Multiple myeloma. Nature Reviews Disease Primers. 2017;3:17046. DOI: 10.1038\/nrdp.2017.46","DOI":"10.1038\/nrdp.2017.46"},{"key":"ref=4","doi-asserted-by":"crossref","unstructured":"Kyle RA, Rajkumar SV.\u00a0Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma. Leukemia. 2009;23:3-9. DOI: 10.1038\/leu.2008.291","DOI":"10.1038\/leu.2008.291"},{"key":"ref=5","doi-asserted-by":"crossref","unstructured":"R\u00edos-Tamayo R, S\u00e1nchez MJ, Garc\u00eda de Veas JL, Rodr\u00edguez T, Puerta JM, Chang-Chan YL, et\u00a0al. Light chain multiple myeloma: A single institution series. Journal of Leukemia. 2015;3:184. DOI: 10.4172\/2329-6917.1000184","DOI":"10.4172\/2329-6917.1000184"},{"key":"ref=6","doi-asserted-by":"crossref","unstructured":"Zhang JJ, Sun WJ, Huang ZX, Chen SL, Zhong YP, Hu Y, et\u00a0al. Light chain multiple myeloma, clinic features, responses to therapy and survival in a long-term study. World Journal of Surgical Oncology. 2014;12:234. DOI: 10.1186\/1477-7819-12-234","DOI":"10.1186\/1477-7819-12-234"},{"key":"ref=7","doi-asserted-by":"crossref","unstructured":"Blad\u00e9 J, Kyle RA.\u00a0Nonsecretory myeloma, immunoglobulin D myeloma, and plasma cell leukemia. Hematology\/Oncology Clinics of North America. 1999;13:1259-1272","DOI":"10.1016\/S0889-8588(05)70125-8"},{"key":"ref=8","doi-asserted-by":"crossref","unstructured":"Chawla SS, Kumar SK, Dispenzieri A, Greenberg AJ, Larson DR, Kyle RA, et\u00a0al. Clinical course and prognosis of non-secretory multiple myeloma. European Journal of Hematology. 2015;95:57-64. DOI: 10.1111\/ejh.12478","DOI":"10.1111\/ejh.12478"},{"key":"ref=9","doi-asserted-by":"crossref","unstructured":"Landgren O, Kyle RA, Pfeiffer RM, Katzmann JA, Caporaso NE, Hayes RB, et\u00a0al. Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study. Blood. 2009;113:5412-5417. DOI: 1182\/blood-2008-12-194241","DOI":"10.1182\/blood-2008-12-194241"},{"key":"ref=10","doi-asserted-by":"crossref","unstructured":"Weiss BM, Abadie J, Verma P, Howard RS, Kuehl M.\u00a0A monoclonal gammopathy precedes multiple myeloma in most patients. Blood. 2009;113:5418-5422. DOI: 10.1182\/blood-2008-12-195008","DOI":"10.1182\/blood-2008-12-195008"},{"key":"ref=11","doi-asserted-by":"crossref","unstructured":"Kyle RA, Therneau TM, Rajkumar SV, Offord JR, Larson DR, Plevak MF, et\u00a0al. A long-term study of prognosis in monoclonal gammopathy of undetermined significance. The New England Journal of Medicine. 2002;346:564-569","DOI":"10.1056\/NEJMoa01133202"},{"key":"ref=12","doi-asserted-by":"crossref","unstructured":"Rajkumar SV, Landgren O, Mateos MV.\u00a0Smoldering multiple myeloma. Blood. 2015;125:3069-3075. DOI: 10.1182\/blood-2014-09-568899","DOI":"10.1182\/blood-2014-09-568899"},{"key":"ref=13","doi-asserted-by":"crossref","unstructured":"Kristinsson SY, Landgren O, Dickman PW, Derolf AR, Bj\u00f6rkholm M.\u00a0Patterns of survival in multiple myeloma: A population-based study of patients diagnosed in Sweden from 1973 to 2003. Journal of Clinical Oncology. 2007;25:1993-1999. DOI: 10.1200\/JCO.2006.09.0100","DOI":"10.1200\/JCO.2006.09.0100"},{"key":"ref=14","doi-asserted-by":"crossref","unstructured":"R\u00edos-Tamayo R, S\u00e1nchez MJ, Puerta JM, Sainz J, Chang-Chan DY, Rodr\u00edguez T, et\u00a0al. Trends in survival of multiple myeloma: A thirty-year population-based study in a single institution. Cancer Epidemiology. 2015;39:693-699. DOI: 10.1016\/j.canep.2015.08.002","DOI":"10.1016\/j.canep.2015.08.002"},{"key":"ref=15","doi-asserted-by":"crossref","unstructured":"Turesson I, Velez R, Kristinsson SY, Landgren O.\u00a0Patterns of improved survival in patients with multiple myeloma in the twenty-first century: A population-based study. Journal of Clinical Oncology. 2010;28:830-834. DOI: 10.1200\/JCO.2009.25.4177","DOI":"10.1200\/JCO.2009.25.4177"},{"key":"ref=16","doi-asserted-by":"crossref","unstructured":"Greipp PR, San Miguel J, Durie BGM, Crowley JJ, Barlogie B, Blad\u00e9 J, et\u00a0al. International staging system for multiple myeloma. Journal of Clinical Oncology. 2005;23:3412-3420. DOI: 10.1200\/JCO.2005.04.242","DOI":"10.1200\/JCO.2005.04.242"},{"key":"ref=17","doi-asserted-by":"crossref","unstructured":"Palumbo A, Avet-Loiseau H, Oliva S, Lokhorst HM, Goldschmidt H, Rosi\u00f1ol L, et\u00a0al. Revised international staging system forMultiple myeloma: A report from international myeloma working group. Journal of Clinical Oncology. 2015;33:2863-2869. DOI: 10.1200\/JCO.2015.61.2267","DOI":"10.1200\/JCO.2015.61.2267"},{"key":"ref=18","doi-asserted-by":"crossref","unstructured":"R\u00edos-Tamayo R, Romero A, Puerta JM, Gonz\u00e1lez PA, L\u00f3pez-Fern\u00e1ndez E, Moratalla L, et\u00a0al. ISS versus R-ISS for risk stratification of multiple myeloma patients undergoing autologous stem cell transplant. Journal of Leukemia. 2015;3:189. DOI: 10.4172\/2329-6917.1000189","DOI":"10.4172\/2329-6917.1000189"},{"key":"ref=19","doi-asserted-by":"crossref","unstructured":"Chng WJ, Dispenzieri A, Chim C-S, Fonseca R, Goldschmidt H, Lentzsch S, et\u00a0al. IMWG consensus on risk stratification in multiple myeloma. Leukemia. 2014;28:269-277. DOI: 10.1038\/leu.2013.247","DOI":"10.1038\/leu.2013.247"},{"key":"ref=20","doi-asserted-by":"crossref","unstructured":"Usmani SZ, Rodriguez-Otero P, Bhutani M, Mateos MV, San Miguel J.\u00a0Defining and treating high-risk multiple myeloma. Leukemia. 2015;29:2119-2125. DOI: 10.1038\/leu.2015.209","DOI":"10.1038\/leu.2015.209"},{"key":"ref=21","doi-asserted-by":"crossref","unstructured":"Alexander DD, Mink PJ, Adami HO, Cole P, Mandel JS, Oken MM, et\u00a0al. Multiple myeloma: A review of the epidemiologic literature. International Journal of Cancer. 2007;120:40-61. DOI: 10.1002\/ijc.22718","DOI":"10.1002\/ijc.22718"},{"key":"ref=22","doi-asserted-by":"crossref","unstructured":"Kyle RA, Rajkumar SV.\u00a0Epidemiology of the plasma-cell disorders. Best Practice and Research Clinical Haematology. 2007;20:637-664. DOI: 10.1016\/j.beha.2007.08.001","DOI":"10.1016\/j.beha.2007.08.001"},{"key":"ref=23","doi-asserted-by":"crossref","unstructured":"Greenberg AJ, Rajkumar SV, Therneau TM, Singh PP, Dispenzieri A, Kumar SK.\u00a0Relationship between initial clinical presentation and the molecular cytogenetic classification of myeloma. Leukemia. 2014;28:398-403. DOI: 10.1038\/leu.2013.258","DOI":"10.1038\/leu.2013.258"},{"key":"ref=24","unstructured":"R\u00edos-Tamayo R, Sainz J, Alba AM, Cruz AJ, P\u00e9rez JA, Morente E, et\u00a0al. The impact of the type of myeloma-defining event on early mortality and survival. In: EHA 21th;9-12 June 2016; Copenhagen. Denmark: Haematologica. 2016;100(s.1):pp. 544-545"},{"key":"ref=25","doi-asserted-by":"crossref","unstructured":"Egan JB, Shi C-X, Tembe W, Christoforides A, Kurdoglu A, Sinari S, et\u00a0al. Whole-genome sequencing of multiple myeloma from diagnosis to plasma cell leukemia reveals genomic initiating events, evolution, and clonal tides. Blood. 2012;120:1060-1066. DOI: 10.1182\/blood-2012-01-405977","DOI":"10.1182\/blood-2012-01-405977"},{"key":"ref=26","doi-asserted-by":"crossref","unstructured":"Corre J, Munshi N, Avet-Loiseau H.\u00a0Genetics of multiple myeloma: Another heterogeneity level? Blood. 2015;125:1870-1876. DOI: 10.1182\/blood-2014-10-567370","DOI":"10.1182\/blood-2014-10-567370"},{"key":"ref=27","doi-asserted-by":"crossref","unstructured":"Keats JJ, Chesi M, Egan JB, Garbitt VM, Palmer SE, Braggio E, et\u00a0al. Clonal competition with alternating dominant in multiple myeloma. Blood. 2012;120:1067-1076. DOI: 10.1182\/blood-2012-01-405985","DOI":"10.1182\/blood-2012-01-405985"},{"key":"ref=28","doi-asserted-by":"crossref","unstructured":"Melchor L, Brioli A, Wardell CP, Murison A, Potter NE, Kaiser MF, et\u00a0al. Single-cell genetic analysis reveals the composition of initiating clones and phylogenetic patterns of branching and parallel evolution in myeloma. Leukemia. 2014;28:1705-1715. DOI: 10.1038\/leu.2014.13","DOI":"10.1038\/leu.2014.13"},{"key":"ref=29","doi-asserted-by":"crossref","unstructured":"Lahuerta JJ, Paiva B, Vidriales MB, Cord\u00f3n L, Cedena MT, Puig N, et\u00a0al. Depth of response in multiple myeloma: A pooled analysis of three PETHEMA\/GEM clinical trials. Journal of Clinical Oncology. 2017;35:2900-2910. DOI: 10.1200\/JCO.2016.69.2517","DOI":"10.1200\/JCO.2016.69.2517"},{"key":"ref=30","doi-asserted-by":"crossref","unstructured":"Kumar S, Paiva B, Anderson KC, Durie B, Landgren O, Moreau P, et\u00a0al. International myeloma working group consensus criteria for response and minimal residual disease assessment in multiple myeloma. The Lancet Oncology. 2016;17:e328-e346. DOI: 10.1016\/S1470-2045(16)30206-6","DOI":"10.1016\/S1470-2045(16)30206-6"},{"key":"ref=31","doi-asserted-by":"crossref","unstructured":"Galceran J, Ameijide A, Carulla M, Mateos A, Quir\u00f3s JR, Rojas D, et\u00a0al. Cancer incidence in Spain, 2015. Clinical & Translational Oncology. 2017;19:799-825. DOI: 10.1007\/s12094-016-1607-9","DOI":"10.1007\/s12094-016-1607-9"},{"key":"ref=32","unstructured":"Bray F, Colombet M, Mery L, Pi\u00f1eros M, Znaor A, Zanetti R, Ferlay J, editors. Cancer Incidence in Five Continents, Vol. XI (electronic version). Lyon: International Agency for Research on Cancer; 2017. Available from: http:\/\/ci5.iarc.fr. [Accessed December 9, 2017]"},{"key":"ref=33","doi-asserted-by":"crossref","unstructured":"Siegel RL, Miller KD, Jemal A.\u00a0Cancer statistics, 2017. CA: a Cancer Journal for Clinicians. 2017;67:7-30. DOI: 10.3322\/caac.21387","DOI":"10.3322\/caac.21387"},{"key":"ref=34","doi-asserted-by":"crossref","unstructured":"V\u00e9lez R, Turesson I, Landgren O, Kristinsson SY, Cuzick J.\u00a0Incidence of multiple myeloma in Great Britain, Sweden, and Malm\u00f6, Sweden: The impact of differences in case ascertainment on observed incidence trends. BMJ Open. 2016;6:e009584. DOI: 10.1136\/bmjopen-2015-009584","DOI":"10.1136\/bmjopen-2015-009584"},{"key":"ref=35","doi-asserted-by":"crossref","unstructured":"Turesson I, V\u00e9lez R, Kristinsson SY, Landgren O.\u00a0Patterns of multiple myeloma during the past 5 decades: Stable incidence rates for all age groups in the population but rapidly changing age distribution in the clinic. Mayo Clinic Proceedings. 2010;85:225-230. DOI: 10.4065\/mcp.2009.0426","DOI":"10.4065\/mcp.2009.0426"},{"key":"ref=36","doi-asserted-by":"crossref","unstructured":"Renshaw C, Ketley N, M\u00f8ller H, Davies EA.\u00a0Trends in the incidence and survival of multiple myeloma in South East England 1985-2004. BMC Cancer. 2010;10:74. DOI: 0.1186\/1471-2407-10-74","DOI":"10.1186\/1471-2407-10-74"},{"key":"ref=37","doi-asserted-by":"crossref","unstructured":"Maluskova D, Svobodova I, Kucerova M, Brozova L, Muzik J, Jarkopvsky J, et\u00a0al. Epidemiology of multiple myeloma in the Czech Republic. Klin Oncol. 2017;30(Suppl 2):2S35-2S42. DOI: 10.14735\/amko20172S35","DOI":"10.14735\/amko20172S35"},{"key":"ref=38","doi-asserted-by":"crossref","unstructured":"Blimark CH, Turesson I, Genell A, Ahlberg L, Bj\u00f6rkstrand B, Carlson K, et\u00a0al. Outcome and survival of myeloma patients diagnosed 2008-2015. Real world data on 4904 patients from the Swedish myeloma registry (SMR). Haematologica. 2018;103:506-513. DOI: 10.3324\/haematol.2017.178103","DOI":"10.3324\/haematol.2017.178103"},{"key":"ref=39","doi-asserted-by":"crossref","unstructured":"Huang SY, Yao M, Tang JL, Lee WC, Tsay W, Cheng AL, et\u00a0al. Epidemiology of multiple myeloma in Taiwan. Increasing incidence for the past 25 years and higher prevalence of extramedullary myeloma in patients younger than 55 years. Cancer. 2007;110:896-905. DOI: 10.1002\/cncr.22850","DOI":"10.1002\/cncr.22850"},{"key":"ref=40","doi-asserted-by":"crossref","unstructured":"Lee JH, Lee DS, Lee JJ, Chang YH, Jin JY, Jo DY, et\u00a0al. Multiple myeloma in Korea: Past, present, and future perspectives. Experience of the Korean multiple myeloma working party. International Journal of Haematology. 2010;92:52-57. DOI: 10.1007\/s12185-010-0617-6","DOI":"10.1007\/s12185-010-0617-6"},{"key":"ref=41","doi-asserted-by":"crossref","unstructured":"Greenberg AJ, Vachon CM, Rajkumar SV.\u00a0Disparities in the prevalence, pathogenesis and progression of monoclonal gammopathy of undetermined significance and multiple myeloma between blacks and whites. Leukemia. 2012;26:609-614. DOI: 10.1038\/leu.2011.368","DOI":"10.1038\/leu.2011.368"},{"key":"ref=42","unstructured":"National Cancer Institute. Surveillance, Epidemiology, and End Results Program [Internet]. 2017. Available from: http:\/\/www.seer.cancer.gov [Accessed: December 10, 2017]"},{"key":"ref=43","doi-asserted-by":"crossref","unstructured":"Wang Q, Wang Y, Ji Z, Chen X, Pan Y, Gao G, et\u00a0al. Risk factors for multiple myeloma: A hospital-based case\u2013control study in Northwest China. Cancer Epidemiology. 2012;36:439-444. DOI: 10.1016\/j.canep.2012.05.002","DOI":"10.1016\/j.canep.2012.05.002"},{"key":"ref=44","doi-asserted-by":"crossref","unstructured":"Sergentanis TN, Zagouri F, Tsilimidos G, Tsagianni A, Tseliou M, Dimopoulos MA, et\u00a0al. Risk factors for multiple myeloma: A systematic review of meta-analyses. Clinical Lymphoma Myeloma and Leukemia. 2015;15:563-577. DOI: 10.1016\/j.clml.2015.06.003","DOI":"10.1016\/j.clml.2015.06.003"},{"key":"ref=45","doi-asserted-by":"crossref","unstructured":"Palumbo A, Anderson K.\u00a0Multiple myeloma. The New England Journal of Medicine. 2011;364:1046-1060. DOI: 10.1056\/NEJMra1011442","DOI":"10.1056\/NEJMra1011442"},{"key":"ref=46","doi-asserted-by":"crossref","unstructured":"Kyle RA, Therneau TM, Rajkumar SV, Larson DR, Plevak MF, Offord JR, et\u00a0al. Prevalence of monoclonal gammopathy of undetermined significance. The New England Journal of Medicine. 2006;354:1362-1369. DOI: 10.1056\/NEJMoa054494","DOI":"10.1056\/NEJMoa054494"},{"key":"ref=47","doi-asserted-by":"crossref","unstructured":"Katodritou E, Terpos E, Symeonidis AS, Pouli A, Kelaidi C, Kyrtsonis MC, et\u00a0al. Clinical features, outcome, and prognostic factors for survival and evolution to multiple myeloma of solitary plasmacytomas: A report of the Greek myeloma study group in 97 patients. American Journal of Hematology. 2014;89:803-808. DOI: 10.1002\/ajh.23745","DOI":"10.1002\/ajh.23745"},{"key":"ref=48","doi-asserted-by":"crossref","unstructured":"Sigurdardottir EE, Turesson I, Lund SH, Lindqvist EK, Mailankody S, Korde N, et\u00a0al. The role of diagnosis and clinical follow-up of monoclonal gammopathy of undetermined significance on survival in multiple myeloma. JAMA Oncology. 2015;1:168-174. DOI: 10.1001\/jamaoncol.2015.23","DOI":"10.1001\/jamaoncol.2015.23"},{"key":"ref=49","doi-asserted-by":"crossref","unstructured":"R\u00edos-Tamayo R, Sainz J, Jurado M, Puerta JM, Gonz\u00e1lez PA, Romero A, et\u00a0al. Multiple myeloma with prior precursor disease shows better outcome. In: 57th Meeting of The American Hematology Association; 5-8 December 2015; Orlando. EEUU : Blood. 2015;126. Abstract 1756","DOI":"10.1182\/blood.V126.23.1756.1756"},{"key":"ref=50","doi-asserted-by":"crossref","unstructured":"Bringhen S, Mateos MV, Zweegman S, Larocca A, Falcone AP, Oriol A, et\u00a0al. Age and organ damage correlate with poor survival in myeloma patients: Meta-analysis of 1435 individual patient data from 4 randomized trials. Haematologica. 2013;98:980-987. DOI: 10.3324\/haematol.2012.075051","DOI":"10.3324\/haematol.2012.075051"},{"key":"ref=51","doi-asserted-by":"crossref","unstructured":"Chretien ML, Hebraud B, Cances-Lauwers V, Hulin C, Marit G, Leleu X, et\u00a0al. Age is a prognostic factor even among patients with multiple myeloma younger than 66 years treated with high-dose melphalan: The IFM experience on 2316 patients. Haematologica. 2014;99:1236-1238. DOI: 10.3324\/haematol.2013.098608","DOI":"10.3324\/haematol.2013.098608"},{"key":"ref=52","doi-asserted-by":"crossref","unstructured":"Wildes TM, Rosko A, Tuchman SA.\u00a0Multiple myeloma in older adults: Better prospects, more challenges. Journal of Clinical Oncology. 2014;32:2531-2540. DOI: 10.1200\/JCO.2014.55.1028","DOI":"10.1200\/JCO.2014.55.1028"},{"key":"ref=53","doi-asserted-by":"crossref","unstructured":"Kumar SK, Dispenzieri A, Lacy MQ, Gertz MA, Buadi FK, Pandey S, et\u00a0al. Continued improvement in survival in multiple myeloma: Changes in early mortality and outcomes in older patients. Leukemia. 2014;28:1122-1128. DOI: 10.1038\/leu.2013.313","DOI":"10.1038\/leu.2013.313"},{"key":"ref=54","doi-asserted-by":"crossref","unstructured":"Liwing J, Uttervall K, Lund J, Aldrin A, Blimark C, Carlson K, et\u00a0al. Improved survival in myeloma patients: Starting to close in on the gap between elderly patients and a matched normal population. British Journal of Haematology. 2014;164:684-693. DOI: 10.1111\/bjh.12685","DOI":"10.1111\/bjh.12685"},{"key":"ref=55","doi-asserted-by":"crossref","unstructured":"Kristinsson SY, Anderson WF, Landgren O.\u00a0Improved long-term survival in multiple myeloma up to the age of 80 years. Leukemia. 2014;28:1346-1348. DOI: 10.1038\/leu.2014.23","DOI":"10.1038\/leu.2014.23"},{"key":"ref=56","doi-asserted-by":"crossref","unstructured":"Augustson BM, Begum G, Dunn JA, Barth NJ, Davies F, Morgan G, et\u00a0al. Early mortality after diagnosis of multiple myeloma: Analysis of patients entered onto the United Kingdom Medical Research Council trials between 1980 and 2002-Medical Research Council adult leukaemia working party. Journal of Clinical Oncology. 2005;23:9219-9226. DOI: 10.1200\/JCO.2005.03.2086","DOI":"10.1200\/JCO.2005.03.2086"},{"key":"ref=57","doi-asserted-by":"crossref","unstructured":"R\u00edos-Tamayo R, Sainz J, Mart\u00ednez-L\u00f3pez J, Puerta JM, Chang-Chan DY, Rodr\u00edguez T, et\u00a0al. Early mortality in multiple myeloma: The time-dependent impact of comorbidity. A population-based study in 621 real-life patients. American Journal of Hematology. 2016;91:700-705. DOI: 10.1002\/ajh.24389","DOI":"10.1002\/ajh.24389"},{"key":"ref=58","doi-asserted-by":"crossref","unstructured":"Kumar SK, Rajkumar SV, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, et\u00a0al. Improved survival in multiple myeloma and the impact of novel therapies. Blood. 2008;111:2516-2520. DOI: 10.1182\/blood-2007-10-116129","DOI":"10.1182\/blood-2007-10-116129"},{"key":"ref=59","doi-asserted-by":"crossref","unstructured":"Yusuf AA, Natwick T, Werther W, Felici D, Mahue M, Bridges KR, et\u00a0al. A retrospective analysis to examine factors associated with mortality in Medicare beneficiaries newly diagnosed with multiple myeloma. Current Medical Research and Opinion. 2016;12:1989-1996. DOI: 10.1080\/03007995.2016.1226166","DOI":"10.1080\/03007995.2016.1226166"},{"key":"ref=60","doi-asserted-by":"crossref","unstructured":"Kirtane K, Lee SJ.\u00a0Racial and ethnic disparities in hematologic malignancies. Blood. 2017;130:1699-1705. DOI: 10.1182\/blood-2017-04-778225","DOI":"10.1182\/blood-2017-04-778225"},{"key":"ref=61","doi-asserted-by":"crossref","unstructured":"Kaya H, Peressini B, Jawed I, Martincic D, Elaimy AL, Lamoreaux WT, et\u00a0al. Impact of age, race and decade of treatment on overall survival in a critical population analysis of 40,000 multiple myeloma patients. International Journal of Hematology. 2012;95:64-70. DOI: 10.1007\/s12185-011-0971-z","DOI":"10.1007\/s12185-011-0971-z"},{"key":"ref=62","doi-asserted-by":"crossref","unstructured":"Ailawadhi S, Frank RD, Advani P, Swaika A, Temkit M, Menghani R, et\u00a0al. Racial disparity in utilization of therapeutic modalities among multiple myeloma patients: A SEER-medicare analysis. Cancer Med-US. 2017;6:2876-2885. DOI: 10.1002\/cam4.1246","DOI":"10.1002\/cam4.1246"},{"key":"ref=63","doi-asserted-by":"crossref","unstructured":"Manojlovic Z, Christofferson A, Liang WS, Aldrich J, Washington M, Wong S, et\u00a0al. Comprehensive molecular profiling of 718 multiple myelomas reveals significant differences in mutation frequencies between African and European descent cases. PLoS Genetics. 2017;13:e1007087. DOI: 10.1371\/journal.pgen.1007087","DOI":"10.1371\/journal.pgen.1007087"},{"key":"ref=64","doi-asserted-by":"crossref","unstructured":"Savage D, Lindenbaum J, Van Ryzin J, Struening E, Garret J.\u00a0Race, poverty, and survival in multiple myeloma. Cancer. 1984;54:3085-3094","DOI":"10.1002\/1097-0142(19841215)54:12<3085::AID-CNCR2820541246>3.0.CO;2-Z"},{"key":"ref=65","doi-asserted-by":"crossref","unstructured":"Fiala MA, Finney JD, Liu J, Stockerl-Goldstein KE, Tomasson MH, Vij R, et\u00a0al. Socioeconomic status is independently associated with overall survival in patient with multiple myeloma. Leukemia & Lymphoma. 2015;56:2643-2649. DOI: 10.3109\/10428194.2015.1011156","DOI":"10.3109\/10428194.2015.1011156"},{"key":"ref=66","doi-asserted-by":"crossref","unstructured":"Costa LJ, Brill IK, Brown EE.\u00a0Impact of marital status, insurance status, income, and race\/ethnicity on the survival of younger patients diagnosed with multiple myeloma in the United States. Cancer. 2016;122:3183-3190. DOI: 10.1002\/cncr.30183","DOI":"10.1002\/cncr.30183"},{"key":"ref=67","doi-asserted-by":"crossref","unstructured":"Sun T, Wang S, Sun H, Wen J, An G, Li J.\u00a0Improved survival in multiple myeloma, with a diminishing racial gap and a widening socioeconomic status gap over three decades. Leukemia & Lymphoma. 2018;59:49-58. DOI: 10.1080\/10428194.2017.1335398","DOI":"10.1080\/10428194.2017.1335398"},{"key":"ref=68","doi-asserted-by":"crossref","unstructured":"Ailawadhi S, Bhatia K, Aulakh S, Meghji Z, Chanan-Khan A.\u00a0Equal treatment and outcomes for everyone with multiple myeloma: Are we there yet? Current Hematologic Malignancy Reports. 2017;12:309-316. DOI: 10.1007\/s11899-017-0393-y","DOI":"10.1007\/s11899-017-0393-y"},{"key":"ref=69","doi-asserted-by":"crossref","unstructured":"Lynch HT, Ferrarar K, Barlogie B, Coleman EA, Lynch JF, Weisenburger D, et\u00a0al. Familial myeloma. The New England Journal of Medicine. 2008;359:152-157. DOI: 10.1056\/NEJMoa0708704","DOI":"10.1056\/NEJMoa0708704"},{"key":"ref=70","doi-asserted-by":"crossref","unstructured":"Landgren O, Kristinsson SY, Goldin LR, Caporaso NE, Blimark C, Mellqvist UH, et\u00a0al. Risk of plasma cell and lymphoproliferative disorders among 14 621 first-degree relatives of 4458 patients with monoclonal gammopathy of undetermined significance in Sweden. Blood. 2009;114:791-795. DOI: 10.1182\/blood-2008-12-191676","DOI":"10.1182\/blood-2008-12-191676"},{"key":"ref=71","doi-asserted-by":"crossref","unstructured":"Altieri A, Chen B, Bermejo LR, Castro F, Hemminki K.\u00a0Familial risks and temporal incidence trends of multiple myeloma. European Journal of Cancer. 2006;42:1661-1670. DOI: 10.1016\/j.ejca.2005.11.033","DOI":"10.1016\/j.ejca.2005.11.033"},{"key":"ref=72","doi-asserted-by":"crossref","unstructured":"Coleman EA, Lynch H, Enderlin C, Stewart B, Thom\u00e9 SD, Kennedy R, et\u00a0al. Initial report of family registry of multiple myeloma. Cancer Nursing. 2009;32:456-464. DOI: 10.1097\/NCC.0b013e3181a90168","DOI":"10.1097\/NCC.0b013e3181a90168"},{"key":"ref=73","doi-asserted-by":"crossref","unstructured":"Vachon CM, Kyle RA, Therneau TM, Foreman BJ, Larson DR, Colby CL, et\u00a0al. Increased risk of monoclonal gammopathy in first-degree relatives of patients with multiple myeloma or monoclonal gammopathy of undetermined significance. Blood. 2009;114:785-790. DOI: 10.1182\/blood-2008-12-192575","DOI":"10.1182\/blood-2008-12-192575"},{"key":"ref=74","doi-asserted-by":"crossref","unstructured":"Van Valkenburg MAE, Pruitt GI, Brill IK, Costa L, Ehtsham M, Justement IT, et\u00a0al. Family history of hematologic malignancies and risk of multiple myeloma: Differences by race and clinical features. Cancer Cause Control. 2016;27:81-91. DOI: 10.1007\/s10552-015-0685-2","DOI":"10.1007\/s10552-015-0685-2"},{"key":"ref=75","doi-asserted-by":"crossref","unstructured":"Schinasi LH, Brown EE, Camp NJ, Wang SS, Hofmann JN, Chiu BC, et\u00a0al. Multiple myeloma and family history of lymphohaematopoietic cancers: Results from the international multiple myeloma consortium. British Journal of Haematology. 2016;175:87-101. DOI: 10.1111\/bjh.14199","DOI":"10.1111\/bjh.14199"},{"key":"ref=76","doi-asserted-by":"crossref","unstructured":"Frank C, Fallah M, Chen T, Mai EK, Sundquist J, F\u00f6rsti A, et\u00a0al. Search for familial clustering of multiple myeloma with any cancer. Leukemia. 2016;30:627-632. DOI: 10.1038\/leu.2015.279","DOI":"10.1038\/leu.2015.279"},{"key":"ref=77","unstructured":"International Labour Organization. International Standard Classification of Occupations: ISCO-08. Geneva: ILO; 2012. V1. 420pp"},{"key":"ref=78","doi-asserted-by":"crossref","unstructured":"Gold LS, Milliken K, Stewart P, Purdue M, Severson R, Seixas N, et\u00a0al. Occupation and multiple myeloma: An occupation and industry analysis. American Journal of Industrial Medicine. 2010;53:768-779. DOI: 10.1002\/ajim.20857","DOI":"10.1002\/ajim.20857"},{"key":"ref=79","doi-asserted-by":"crossref","unstructured":"Lope V, P\u00e9rez-G\u00f3mez B, Aragon\u00e9s N, L\u00f3pez-Abente G, Gustavsson P, Plato N, et\u00a0al. Occupation, exposure to chemicals, sensitizing agents, and risk of multiple myeloma in Sweden. Cancer Epidemiology, Biomarkers & Prevention. 2008;17:3123-3127. DOI: 10.1158\/1055-9965.EPI-08-0343","DOI":"10.1158\/1055-9965.EPI-08-0343"},{"key":"ref=80","doi-asserted-by":"crossref","unstructured":"Perrotta C, Staines A, Codd M, Kleefeld S, Crowley D, Mannetje AT, et\u00a0al. Multiple myeloma and lifetime occupation: Results from the EPILYMPH study. Journal of Occupational Medical Toxicology. 2012;7:25. DOI: 10.1186\/1745-6673-7-25","DOI":"10.1186\/1745-6673-7-25"},{"key":"ref=81","doi-asserted-by":"crossref","unstructured":"Takkouche B, Regueira-M\u00e9ndez C, Montes-Mart\u00ednez A.\u00a0Risk of cancer among hairdressers and related workers: A meta-analysis. International Journal of Epidemiology. 2009;38:1512-1531. DOI: 10.1093\/ije\/dyp283","DOI":"10.1093\/ije\/dyp283"},{"key":"ref=82","doi-asserted-by":"crossref","unstructured":"Liu T, Xu Q, Zhang CH, Zhang P.\u00a0Occupational exposure to methylene chloride and risk of cancer: A meta-analysis. Cancer Cause Control. 2006;24:2037-2049. DOI: 10.1007\/s10552-013-0283-0","DOI":"10.1007\/s10552-013-0283-0"},{"key":"ref=83","doi-asserted-by":"crossref","unstructured":"Khuder SA, Mutgi AB.\u00a0Meta-analyses of multiple myeloma and farming. American Journal of Industrial Medicine. 1997;32:510-516","DOI":"10.1002\/(SICI)1097-0274(199711)32:5<510::AID-AJIM11>3.0.CO;2-5"},{"key":"ref=84","doi-asserted-by":"crossref","unstructured":"Perrotta C, Staines A, Cocco P.\u00a0Multiple myeloma and farming. A systematic review of 30 years of research. Where next? Journal of Occupational Medicine and Toxicology. 2008;3:27. DOI: 10.1186\/1745-6673-3-27","DOI":"10.1186\/1745-6673-3-27"},{"key":"ref=85","doi-asserted-by":"crossref","unstructured":"Ghafari M, Cheraghi Z, Doosti-Irani A.\u00a0Occupational risk factors among Iranian farmworkers: A review of the available evidence. Epidemiology and Health. 2017;39:e2017027. DOI: 10.4178\/epih.e2017027","DOI":"10.4178\/epih.e2017027"},{"key":"ref=86","doi-asserted-by":"crossref","unstructured":"Kachuri L, Harris MA, MacLeod JS, Tjepkema M, Peters PA, Demers PA.\u00a0Cancer risks in a population-based study of 70,570 agricultural workers: Results from the Canadian census health and environment cohort (CanCHEC). BMC Cancer. 2017;17:343. DOI: 10.1186\/s12885-017-3346-x","DOI":"10.1186\/s12885-017-3346-x"},{"key":"ref=87","doi-asserted-by":"crossref","unstructured":"Louis LM, Lerro CC, Friesen MC, Andreotti G, Koutros S, Sandler DP, et\u00a0al. A prospective study of cancer risk among agricultural health study farm spouses associated with personal use of organochlorine insecticides. Environmental Health. 2017;16:95. DOI: 10.1186\/s12940-017-0298-1","DOI":"10.1186\/s12940-017-0298-1"},{"key":"ref=88","doi-asserted-by":"crossref","unstructured":"Chang ET, Delzell E.\u00a0Systematic review and meta-analysis of glyphosate exposure and risk of lymphohematopoietic cancers. Journal of Environmental Science and Health. Part. B. 2016;51:402-428. DOI: 10.1080\/03601234.2016.1142748","DOI":"10.1080\/03601234.2016.1142748"},{"key":"ref=89","doi-asserted-by":"crossref","unstructured":"R\u00edos-Tamayo R, Sainz J, Jim\u00e9nez-Mole\u00f3n JJ, Jurado M.\u00a0Obesity and multiple myeloma: What do the data tell us? Journal of Leukemia. 2014;2:e109. DOI: 10.4172\/2329-6917.1000e109","DOI":"10.4172\/2329-6917.1000e109"},{"key":"ref=90","unstructured":"Brook C, Thomas CC, Henley SJ, Massetti GM, Galuska DA, Agurs-Collins T, et\u00a0al. Vital signs: Trends in incidence of cancers associated with overweight and obesity \u2014 United States, 2005-2014. MMWR 2017;66:39. Available from: https:\/\/www.cdc.gov\/mmwr. [Accessed: October 3, 2017]"},{"key":"ref=91","doi-asserted-by":"crossref","unstructured":"Larsson SC, Wolk A.\u00a0Body mass index and risk of multiple myeloma: A meta-analysis. International Journal of Cancer. 2007;121:2512-2516. DOI: 10.1002\/ijc.22968","DOI":"10.1002\/ijc.22968"},{"key":"ref=92","doi-asserted-by":"crossref","unstructured":"Renehan AG, Tyson M, Egger M, Heller RF, Zwahlen M.\u00a0Body-mass index and incidence of cancer: A systematic review and meta-analysis of prospective observational studies. Lancet. 2008;371:569-578. DOI: 10.1016\/S0140-6736(08)60269-X","DOI":"10.1016\/S0140-6736(08)60269-X"},{"key":"ref=93","doi-asserted-by":"crossref","unstructured":"Wallin A, Larsson SC.\u00a0Body mass index and risk of multiple myeloma: A meta-analysis of prospective studies. European Journal of Cancer. 2011;47:1606-1615. DOI: 10.1016\/j.ejca.2011.01.020","DOI":"10.1016\/j.ejca.2011.01.020"},{"key":"ref=94","unstructured":"R\u00edos-Tamayo R, Jim\u00e9nez-Mole\u00f3n JJ, Sainz J, L\u00f3pez F, Rivera AB, S\u00e1nchez MJ, et\u00a0al. Multiple myeloma and obesity: A meta-analysis. In: EHA 16th;9-12 June 2011; London.UK: Haematologica -The Hematology Journal. 2011;96,s2:pp. s585-586"},{"key":"ref=95","doi-asserted-by":"crossref","unstructured":"Polednak AP.\u00a0Estimating the number of U.S. incident cancers attributable to obesity and the impact on temporal trends in incidence rates for obesity-related cancers. Cancer Detection and Prevention. 2008;32:190-199. DOI: 10.1016\/j.cdp.2008.08.004","DOI":"10.1016\/j.cdp.2008.08.004"},{"key":"ref=96","doi-asserted-by":"crossref","unstructured":"The Global BMI Mortality Collaboration. Body-mass index and all-cause mortality: Individual participant-data meta-analysis of 239 prospective studies in four continents. Lancet. 2016;388:776-786. DOI: 10.1016\/S0140-6736(16)30175-1","DOI":"10.1016\/S0140-6736(16)30175-1"},{"key":"ref=97","doi-asserted-by":"crossref","unstructured":"Yang L, Drake BF, Colditz GA. Obesity and other cancers. Journal of Clinical Oncology. 2016;34:4231-4237. DOI: 10.1200\/JCO.2016.68.4837","DOI":"10.1200\/JCO.2016.68.4837"},{"key":"ref=98","doi-asserted-by":"crossref","unstructured":"R\u00edos-Tamayo R, Sainz J, Jim\u00e9nez-Mole\u00f3n JJ, Jurado M.\u00a0Type 2 diabetes and multiple myeloma: The latest insights. Journal of Leukemia. 2014;2:e110. DOI: 10.4172\/2329-6917.1000e110","DOI":"10.4172\/2329-6917.1000e110"},{"key":"ref=99","doi-asserted-by":"crossref","unstructured":"Castillo JJ, Mull N, Reagan JL, Nemr S, Mitri J.\u00a0Increased incidence of non-Hodgkin lymphoma, leukemia, and myeloma in patients with diabetes mellitus type 2: A meta-analysis of observational studies. Blood. 2012;119:4845-4850. DOI: 10.1182\/blood-2011-06-362830","DOI":"10.1182\/blood-2011-06-362830"},{"key":"ref=100","doi-asserted-by":"crossref","unstructured":"R\u00edos-Tamayo R, Lupia\u00f1ez CB, Campa D, Martino A, Mart\u00ednez-L\u00f3pez J, Mart\u00ednez-Bueno M, et\u00a0al. Type 2 diabetes-related variants influence the risk of developing multiple myeloma: Results from the IMMEnSE consortium. Endocrine-Related Cancer. 2015;22:545-559. DOI: 10.1530\/ERC-15-0029","DOI":"10.1530\/ERC-15-0029"},{"key":"ref=101","doi-asserted-by":"crossref","unstructured":"Wu W, Merriman K, Nabaah A, Seval N, Seval D, Lin H, et\u00a0al. The association of diabetes and anti-diabetic medications with clinical outcomes in multiple myeloma. British Journal of Cancer. 2014;111:628-636. DOI: 10.1038\/bjc.2014.307","DOI":"10.1038\/bjc.2014.307"},{"key":"ref=102","doi-asserted-by":"crossref","unstructured":"R\u00edos-Tamayo R, Lupia\u00f1ez CB, Campa D, Hielscher T, Weinhold N, Mart\u00ednez-L\u00f3pez J, et\u00a0al. A common variant within the HNF1B gene is associated with overall survival of multiple myeloma patients: Results from the IMMEnSE consortium and meta-analysis. Oncotarget. 2016;7:59029-59048. DOI: 10.18632\/oncotarget.10665","DOI":"10.18632\/oncotarget.10665"},{"key":"ref=103","doi-asserted-by":"crossref","unstructured":"Praud D, Rota M, Rehm J, Shield K, Zatonski W, Hashibe M, et\u00a0al. Cancer incidence and mortality attributable to alcohol consumption. International Journal of Cancer. 2016;138:1380-1387. DOI: 10.1002\/ijc.29890","DOI":"10.1002\/ijc.29890"},{"key":"ref=104","doi-asserted-by":"crossref","unstructured":"Psaltopoulou T, Sergentanis TN, Sergentanis IN, Karadimitris A, Terpos E, Dimopoulos MA.\u00a0Alcohol intake, alcoholic beverage type and multiple myeloma risk: A meta-analysis of 26 observational studies. Leukemia & Lymphoma. 2015;56:1484-1501. DOI: 10.3109\/10428194.2014.956312","DOI":"10.3109\/10428194.2014.956312"},{"key":"ref=105","doi-asserted-by":"crossref","unstructured":"Rota M, Porta L, Pelucchi C, Negri E, Bagnardi V, Bellocco R, et\u00a0al. Alcohol drinking and multiple myeloma risk \u2013 A systematic review and meta-analysis of the dose\u2013risk relationship. European Journal of Cancer Prevention. 2014;23:113-121. DOI: 10.1097\/CEJ.0000000000000001","DOI":"10.1097\/CEJ.0000000000000001"},{"key":"ref=106","doi-asserted-by":"crossref","unstructured":"Andreotti G, Birmann B, De Roos AJ, Spinelli J, Cozen W, Camp NJ, et\u00a0al. A pooled analysis of alcohol consumption and risk of multiple myeloma in the international multiple myeloma consortium. Cancer Epidemiology, Biomarkers & Prevention. 2013;22:1620-1627. DOI: 10.1158\/1055-9965.EPI-13-0334","DOI":"10.1158\/1055-9965.EPI-13-0334"},{"key":"ref=107","doi-asserted-by":"crossref","unstructured":"Ji J, Sundquist J, Sundquist K.\u00a0Alcohol consumption has a protective effect against hematological malignancies: A population-based study in Sweden including 420,489 individuals with alcohol use disorders. Neoplasia. 2014;16:229-234. DOI: 10.1016\/j.neo.2014.03.003","DOI":"10.1016\/j.neo.2014.03.003"},{"key":"ref=108","doi-asserted-by":"crossref","unstructured":"Andreotti G, Birmann B, Cozen W, De Roos AJ, Chiu BCH, Costas L, et\u00a0al. A pooled analysis of cigarette smoking and risk of multiple myeloma from the international multiple myeloma consortium. Cancer Epidemiology, Biomarkers & Prevention. 2014;24:631-634. DOI: 10.1158\/1055-9965.EPI-14-1145","DOI":"10.1158\/1055-9965.EPI-14-1145"},{"key":"ref=109","doi-asserted-by":"crossref","unstructured":"Psaltopoulou T, Sergentanis TN, Kanellias N, Kanavidis P, Terpos E, Dimopoulos MA.\u00a0Tobacco smoking and risk of multiple myeloma: A meta-analysis of 40 observational studies. International Journal of Cancer. 2013;132:2413-2431. DOI: 10.1002\/ijc.27898","DOI":"10.1002\/ijc.27898"},{"key":"ref=110","doi-asserted-by":"crossref","unstructured":"Chen P, Du ZL, Zhang Y, Liu B, Gui Z, Lou JX, et\u00a0al. Association of VEGF and VDR gene- gene and gene- smoking interaction on risk of multiple myeloma in Chinese Han population. Oncotarget. 2017;8:36509-36516. DOI: 10.18632\/oncotarget.16510","DOI":"10.18632\/oncotarget.16510"},{"key":"ref=111","doi-asserted-by":"crossref","unstructured":"Wang YZ, Wu QJ, Zhu J, Wu L.\u00a0Fish consumption and risk of myeloma: A meta-analysis of epidemiological studies. Cancer Cause Control. 2015;26:1307-1314. DOI: 10.1007\/s10552-015-0625-1","DOI":"10.1007\/s10552-015-0625-1"},{"key":"ref=112","doi-asserted-by":"crossref","unstructured":"Ugai T, Matsuo K, Sawada N, Iwasaki M, Yamaji T, Shimazu T, et\u00a0al. Coffee and green tea consumption and subsequent risk of malignant lymphoma and multiple myeloma in Japan: The Japan public health Center-based prospective study. Cancer Epidemiology, Biomarkers & Prevention. 2017;26:1352-1356. DOI: 10.1158\/1055-9965.EPI-17-0231","DOI":"10.1158\/1055-9965.EPI-17-0231"},{"key":"ref=113","doi-asserted-by":"crossref","unstructured":"Sergentanis TN, Psaltopoulou T, Ntanasis-Stathopoulos I, Liaskas A, Tzanninis IG, Dimopoulos MA.\u00a0Consumption of fruits, vegetables, and risk of hematological malignancies: A systematic review and meta-analysis of prospective studies. Leukemia Lymphoma. 2018;59:434-447. DOI: 10.1080\/10428194.2017.1339873","DOI":"10.1080\/10428194.2017.1339873"},{"key":"ref=114","doi-asserted-by":"crossref","unstructured":"Lwin ST, Olechnowicz SWZ, Fowler JA, Edwards CM.\u00a0Diet-induced obesity promotes a myeloma-like condition. Leukemia. 2015;29:507-510. DOI: 10.1038\/leu.2014.295","DOI":"10.1038\/leu.2014.295"},{"key":"ref=115","doi-asserted-by":"crossref","unstructured":"Mayne ST, Playdon MC, Rock CL.\u00a0Diet, nutrition, and cancer: Past, present and future. Nature Reviews. Clinical Oncology. 2016;13:504-515. DOI: 10.1038\/nrclinonc.2016.24","DOI":"10.1038\/nrclinonc.2016.24"},{"key":"ref=116","doi-asserted-by":"crossref","unstructured":"Smith L, McCourt O, Henrich M, Paton B, Yong K, Wardle J, et\u00a0al. Multiple myeloma and physical activity: A scoping review. BMJ Open. 2015;5:e009576. DOI: 10.1136\/bmjopen-2015-009576","DOI":"10.1136\/bmjopen-2015-009576"},{"key":"ref=117","doi-asserted-by":"crossref","unstructured":"Moore SC, Lee IM, Weiderpass E, Campbell PT, Sampson JN, Kitahara CM, et\u00a0al. Association of leisure-time physical activity with risk of 26 types of cancer in 1.44 million adults. JAMA Internal Medicine. 2016;176:816-825. DOI: 10.1001\/jamainternmed.2016.1548","DOI":"10.1001\/jamainternmed.2016.1548"},{"key":"ref=118","doi-asserted-by":"crossref","unstructured":"Patel AV, Hildebrand JS, Campbell PT, Teras LR, Craft LL, McCullough ML, et\u00a0al. Leisure-time spent sitting and site-specific cancer incidence in a large U.S. cohort. Cancer Epidemiology, Biomarkers & Prevention. 2015;24:1350-1359. DOI: 10.1158\/1055-9965.EPI-15-0237","DOI":"10.1158\/1055-9965.EPI-15-0237"},{"key":"ref=119","doi-asserted-by":"crossref","unstructured":"Gan JH, Sim CYL, Santorelli LA.\u00a0The effectiveness of exercise programmes in patients with multiple myeloma: A literature review. Critical Reviews in Oncology\/Hematology. 2016;98:275-289. DOI: 10.1016\/j.critrevonc.2015.11.005","DOI":"10.1016\/j.critrevonc.2015.11.005"},{"key":"ref=120","unstructured":"Franceschi S, Lise M, Tr\u00e9po C, Berthillon P, Chuang SC, Nieters A, et\u00a0al. Infection with hepatitis B and C viruses and risk of lymphoid malignancies in the European prospective investigation into cancer and nutrition (EPIC). Cancer Epidemiology, Biomarkers & Prevention. 2011;20:208-214. DOI: 10.1158\/1055-9965.EPI- 10-0889"},{"key":"ref=121","doi-asserted-by":"crossref","unstructured":"Abe SK, Inoue M, Sawada N, Iwasaki M, Shimazu T, Yamaji T, et\u00a0al. Hepatitis B and C virus infection and risk of lymphoid malignancies: A population-based cohort study (JPHC study). Cancer Epidemiology. 2015;39:562-566. DOI: 10.1016\/j.canep.2015.06.002","DOI":"10.1016\/j.canep.2015.06.002"},{"key":"ref=122","doi-asserted-by":"crossref","unstructured":"Wen J, Tao W, Kuiatse I, Lin P, Feng Y, Jones RJ, et\u00a0al. Dynamic balance of multiple myeloma clonogenic side population cell percentages controlled by environmental conditions. International Journal of Cancer. 2015;136:991-1002. DOI: 10.1002\/ijc.29078","DOI":"10.1002\/ijc.29078"},{"key":"ref=123","doi-asserted-by":"crossref","unstructured":"Nuyujukian DS, Voutsinas J, Bernstein L, Wang SS.\u00a0Medication use and multiple myeloma risk in Los Angeles County. Cancer Cause Control. 2014;25:1233-1237. DOI: 10.1007\/s10552-014-0424-0","DOI":"10.1007\/s10552-014-0424-0"},{"key":"ref=124","doi-asserted-by":"crossref","unstructured":"Hemminki K, Liu X, F\u00f6rsti A, Ji J, Sundquist J, Sundquist K.\u00a0Effect of autoimmune diseases on incidence and survival in subsequent multiple myeloma. Journal of Hematology & Oncology. 2012;5:59. DOI: 10.1186\/1756-8722-5-59","DOI":"10.1186\/1756-8722-5-59"},{"key":"ref=125","doi-asserted-by":"crossref","unstructured":"Dalamaga M, Karmaniolas K, Papadavid E, Pelecanos N, Migdalis I.\u00a0Association of thyroid disease and thyroid autoimmunity with multiple myeloma risk: A case-control study. Leukemia Lymphoma. 2008;49:1545-1552. DOI: 10.1080\/10428190802165946","DOI":"10.1080\/10428190802165946"},{"key":"ref=126","doi-asserted-by":"crossref","unstructured":"Brown LM, Gridley G, Check D, Landgren O.\u00a0Risk of multiple myeloma and monoclonal gammopathy of undetermined significance among white and black male United States veterans with prior autoimmune, infectious, inflammatory, and allergic disorders. Blood. 2008;111:3388-3394. DOI: 10.1182\/blood-2007-10-121285","DOI":"10.1182\/blood-2007-10-121285"},{"key":"ref=127","doi-asserted-by":"crossref","unstructured":"Faller E, Chapman L, Enright H, Browne P, McHugh J, Desmond R.\u00a0Immune thrombocytopenia purpura associated with multiple myeloma. Annals of Hematology. 2016;95:1371-1372. DOI: 10.1007\/s00277-016-2694-y","DOI":"10.1007\/s00277-016-2694-y"},{"key":"ref=128","unstructured":"Hsing AW, Hansson LE, McLaughlin JK, Nyren O, Blot WJ, Ekbom A, et\u00a0al. Pernicious anemia and subsequent cancer. Cancer. 1993;71:745-750. DOI: 10.1002\/10970142(19930201)71:3<745::AID-CNCR2820710316>3.0.CO;2-1"},{"key":"ref=129","doi-asserted-by":"crossref","unstructured":"Lindqvist EK, Landgren O, Lund SH, Turesson I, Hultcrantz M, Goldin L, et\u00a0al. History of autoimmune disease is associated with impaired survival in multiple myeloma and monoclonal gammopathy of undetermined significance: A population-based study. Annals of Hematology. 2017;96:261-269. DOI: 10.1007\/s00277-016-2859-8","DOI":"10.1007\/s00277-016-2859-8"},{"key":"ref=130","doi-asserted-by":"crossref","unstructured":"Dosani T, Mailankody S, Korde N, Manasanch E, Bhutani M, Tageja N, et\u00a0al. Host-related immunodeficiency in the development of multiple myeloma. Leukemia Lymphoma. DOI: 10.1080\/10428194.2017.1361026","DOI":"10.1080\/10428194.2017.1361026"},{"key":"ref=131","doi-asserted-by":"crossref","unstructured":"Munker R, Shi R, Lin D, Guo S, Hayes TG.\u00a0Multiple myeloma and other malignancies: A pilot study from the Houston VA.\u00a0Clinical Lymphoma Myeloma and Leukemia. 2014;14:102-106. DOI: 10.1016\/j.clml.2013.10.006","DOI":"10.1016\/j.clml.2013.10.006"},{"key":"ref=132","doi-asserted-by":"crossref","unstructured":"R\u00edos-Tamayo R, Sol\u00e9 F, Gasc\u00f3n F.\u00a0Simultaneous occurrence of the 5q- syndrome and multiple myeloma. Clinical and Laboratory Haematology. 2000;22:49-51. DOI: 10.1046\/j.1365-2257.2000.00274.x","DOI":"10.1046\/j.1365-2257.2000.00274.x"},{"key":"ref=133","doi-asserted-by":"crossref","unstructured":"Musto P, Anderson KC, Attal M, Richardson PG, Badros A, Hou J, et\u00a0al. Second primary malignancies in multiple myeloma: An overview and IMWG consensus. Annals of Oncology. 2017;28:228-245. DOI: 10.1093\/annonc\/mdw606","DOI":"10.1093\/annonc\/mdw606"},{"key":"ref=134","doi-asserted-by":"crossref","unstructured":"Blad\u00e9 J, Kyle RA, Greipp PR.\u00a0Presenting features and prognosis in 72 patients with multiple myeloma who were younger than 40 years. British Journal of Haematology. 1996;93:345-351. DOI: 10.1046\/j.1365-2141.1996.5191061.x","DOI":"10.1046\/j.1365-2141.1996.5191061.x"},{"key":"ref=135","doi-asserted-by":"crossref","unstructured":"Dimopoulos MA, Delimpasi S, Katodritou E, Vassou A, Kyrtsonis MC, Repossis P, et\u00a0al. Significant improvement in the survival of patients with multiple myeloma presenting with severe renalnimpairment after the introduction of novel agents. Annals of Oncology. 2014;25:195-200. DOI: 10.1093\/annonc\/mdt483","DOI":"10.1093\/annonc\/mdt483"},{"key":"ref=136","doi-asserted-by":"crossref","unstructured":"R\u00edos-Tamayo R, Gonz\u00e1lez-Silva M, Molina E, Garc\u00eda-Fern\u00e1ndez JR, Clavero ME, Dur\u00e1n JM, et\u00a0al. The impact of the type of hospital on survival of multiple myeloma patients: The MICORE study. Revista Cl\u00ednica Espa\u00f1ola. 2013;213:330-335. DOI: 10.1016\/j.rce.2013.02.014","DOI":"10.1016\/j.rce.2013.02.014"},{"key":"ref=137","doi-asserted-by":"crossref","unstructured":"Go RS, Bartley AC, Crowson CS, Shah ND, Habermann EB, Holton SJ, et\u00a0al. Association between treatment facility volume and mortality of patients with multiple myeloma. Journal of Clinical Oncology. 2017;35:598-604. DOI: 10.1200\/JCO.2016.68.3805","DOI":"10.1200\/JCO.2016.68.3805"},{"key":"ref=138","doi-asserted-by":"crossref","unstructured":"R\u00edos-Tamayo R, Sainz J, Jurado M.\u00a0Comparative baseline health-related quality of life in real-life patients with monoclonal gammopathies. Journal of Leukemia. 2015;3:196. DOI: 10.4172\/2329-6917.1000196","DOI":"10.4172\/2329-6917.1000196"},{"key":"ref=139","doi-asserted-by":"crossref","unstructured":"Drayson MT, Bowcock S, Planche T, Iqbal G, Wood J, Raynes K, et\u00a0al. Tackling early morbidity and mortality in myeloma (TEAMM): Assessing the benefit of antibiotic prophylaxis and its effect on healthcare associated infections in 977 patients. In: 59th Meeting of The American Hematology Association; 3-6 December 2017;Atlanta. EEUU.\u00a0Blood. 2017;130(Suppl 1). Abstract 903","DOI":"10.1182\/blood.V130.Suppl_1.903.903"},{"key":"ref=140","unstructured":"Mateos MV, Mart\u00ednez-L\u00f3pez J, Rodr\u00edguez-Otero P, Ocio EM, Gonz\u00e1lez MS, Oriol A, et\u00a0al. Curative Strategy for High-Risk Smoldering Myeloma (GEM-CESAR): Carfilzomib, Lenalidomide and Dexamethasone (KRd) As Induction Followed By HDT-ASCT, Consolidation with Krd and Maintenance with Rd. In: 59th Meeting of The American Hematology Association; 3-6 December 2017;Atlanta. EEUU : Blood. 2017;130(Suppl 1). Abstract 402"},{"key":"ref=141","doi-asserted-by":"crossref","unstructured":"Ludwig H, Delforge M, Facon T, Einsele H, Gay F, Moreau P, et\u00a0al. Prevention and management of adverse events of novel agents in multiple myeloma: A consensus of the European Myeloma Network. Leukemia. 2017. DOI: 10.1038\/leu.2017.353","DOI":"10.1038\/leu.2017.353"}],"container-title":["Update on Multiple Myeloma"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.intechopen.com\/download\/pdf\/59975","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,11]],"date-time":"2022-09-11T14:45:55Z","timestamp":1662907555000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.intechopen.com\/books\/update-on-multiple-myeloma\/epidemiology-of-multiple-myeloma"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2,20]]},"ISBN":["9781789852172","9781789852189"],"references-count":141,"URL":"https:\/\/doi.org\/10.5772\/intechopen.75396","relation":{},"subject":[],"published":{"date-parts":[[2019,2,20]]}}}